Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization
スポンサーリンク
概要
- 論文の詳細を見る
- 1997-01-24
著者
-
Marquet P.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
HOJA H.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
VERNEUIL B.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
LOTFI H.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
DUPUY J.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
PENICAUT B.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
LACHATRE G.
Service de Pharmacologie et Toxicologie, Chru Dupuytren
-
Hoja H.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Dupuy J.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Lotfi H.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Verneuil B.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Lachatre G.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
-
Penicaut B.
Service De Pharmacologie Et Toxicologie Chru Dupuytren
関連論文
- Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization
- Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry